Pharmaceutical

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.

Jan 13, 2024 - 18:00
Dermavant maps out atopic dermatitis filing after positive Phase III data 
Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.
Read the original article

Tags:

Previous Article

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients

Next Article

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Promising new malaria vaccine for kids approved in Ghana

Promising new malaria vaccine for kids approved in Ghana

Apr 13, 2023

As NIH grant runs out, Dog Aging Project founders look to raise up to $50 million

As NIH grant runs out, Dog Aging Project founders look ...

Jan 24, 2024

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

Eli Lilly to invest $1.8bn in manufacturing capacity in...

Sep 14, 2024